Mode
Text Size
Log in / Sign up
N/A N=126 Randomized Single-blind Treatment

A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia

Schizophrenia · Schizoaffective Disorder

Enrolled (actual)
126
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcome: Primary: Relapses in Participants — 20; 22 Participants — p=0.80

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Device: Smartphone (Behavioral); Treatment as usual (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Dartmouth-Hitchcock Medical Center
Primary completion
Aug 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Relapses in Participants
20; 22 0.80
PRIMARY
Time to Relapse
13.8; NA 0.43
SECONDARY
Psychotic Symptom Severity
26.3; 27.4; 24.9; 25.3; 25.3; 23.7 0.58
SECONDARY
Depression
1.4; 2.1; 1.7; 1.7; 1.4; 1.7 0.84
SECONDARY
Social Functioning
142.0; 135.1; 144.9; 140.0; 145.8; 140.1 0.06

Summary

This study was a 2-arm randomized control trial (RCT) designed to test a multi-modal smartphone data collection system that provided mobile monitoring of schizophrenia to detect early signs of relapse. The RCT compared an arm with participants who received treatment as usual with an arm that received the smartphone system for a year.

Eligibility Criteria

Inclusion Criteria

  • Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria for schizophrenia, schizoaffective disorder, or psychosis not otherwise specified based on a chart diagnosis
  • 18 years or older
  • An inpatient psychiatric hospitalization, daytime psychiatric hospitalization, outpatient crisis management, or short-term psychiatric hospital emergency room within 12 months before study entry
  • Willing and able to provide informed consent

Exclusion Criteria

  • Hearing, vision, or motor impairment that make it impossible to operate a smartphone (determined using a demonstration smartphone for screening)
  • 6th grade reading level (determined by Wide Range Achievement Test- 4th Edition)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01952041). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search